Microbiota and mucosal defense in IBD: an update

Area of Science:

• Gastroenterology
• Microbiology
• Immunology

Background:

• Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are increasing globally.
• IBD pathogenesis involves dysregulated interactions between intestinal microbiota and the host mucosal barrier.
• Deficiencies in mucosal defense structures, such as antimicrobial peptides and the mucus layer, are implicated in IBD.

Purpose of the Study:

• To review current concepts on the etiology of IBD, focusing on microbiota-mucosal barrier interactions.
• To examine the roles of antimicrobial peptides and mucus layer integrity in IBD pathogenesis.
• To discuss the implications of these findings for developing targeted IBD therapies.

Main Methods:

• Literature review of current research on IBD etiology.
• Focus on the function and defects of specific mucosal barrier components (antimicrobial peptides, mucus).
• Analysis of microbiota composition changes and their relation to disease activity and host genetics.

Main Results:

• IBD is characterized by reduced gut bacterial diversity and richness, with altered abundance of specific species.
• The mucus layer in IBD is compromised, allowing bacterial contamination of the epithelium.
• Genetic factors affecting Paneth cells, defensins, and mucus production appear to be primary drivers of mucosal defects in IBD.

Conclusions:

• Dysfunctional interactions between gut microbiota and a defective mucosal barrier are central to IBD.
• Targeting these specific mucosal defense mechanisms represents a promising avenue for future IBD therapies.
• While nutrition plays a role, current therapies do not directly address these primary mucosal defects.